The COVID-19 pandemic has brought the global interdependency of pharmaceutical supply chains into sharp focus, exposing weak links and re-igniting discussions around the value of reshoring production. The U.S. Food and Drug Administration (FDA) reports 72% of facilities manufacturing APIs for American drugs are overseas, with 13% in China. Download our white paper where we discuss effective strategies to secure and de-risk pharmaceutical supply chains and reveal how Curia assures the continual production of urgently needed drugs.View resource
More from Curia
Often, aggressive timelines are imposed on development projects with the aim of getting to First-in-Human trials as soon as possible. However, formulation development can be met with many challenges as biologics are often sensitive molecules with a v...